Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Financing - ideal

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Jul 13, 2022 8:49am

63 Views

Post# 34820146

RE:RE:RE:Financing - ideal

Dies anyone know the current price of the convertible (as of yesterday)?

SPCEO1 wrote: If nothing else, it removes the overhang of another ONO from the stock. But will anyone even notice at this point? The stock should jump a lot on this deal because of the removed dilution overhang, the immediate benefit to cash flow over the next 2 years (maybe three years) and the backing of a major healthcare lender of TH's plans for the future.

palinc2000 wrote:
Need to see the fine prints

tee time in 5 minutes will look thid afternoon

SPCEO1 wrote: My initial reaction is this is perfect. The opposite of the ONO and indicative of confidence in the future of TH. I will have a closer look later.